Doughnut holes and price controls

Area of Science:

• Health Economics
• Pharmaceutical Policy

Background:

• In 2003, pharmaceutical prices in the United States were substantially higher compared to Canada, the United Kingdom, and France.
• This price disparity impacts healthcare costs and patient access to medications.

Purpose of the Study:

• To analyze the cost differences in pharmaceuticals between the US and other developed nations.
• To explore the implications of these price differences for the Medicare program, specifically its prescription drug benefit and the coverage gap (doughnut hole).

Main Methods:

• Comparative analysis of pharmaceutical prices for a standardized market basket of drugs across selected countries in 2003.
• Economic modeling to assess the impact of aligning Medicare prices with international benchmarks.

Main Results:

• Citizens of Canada, the UK, and France paid 34-59% of the prices Americans paid for the same pharmaceuticals in 2003.
• Aligning Medicare prices with these international levels could fund the elimination of the prescription drug benefit's doughnut hole.
• This price alignment would also allow Medicare drug spending to remain within congressionally set limits.

Conclusions:

• Significant cost savings are achievable for Medicare by negotiating lower pharmaceutical prices.
• Policy choices exist for Congress: reduce beneficiary cost-sharing and improve access, or permit higher prices for industry research and development.
• Addressing pharmaceutical price disparities offers a pathway to enhance Medicare benefits and control program expenditures.